Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ADC Therapeutics SA is a pioneering biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment. Its flagship product, ZYNLONTA, targets CD19 for relapsed or refractory B-cell lymphomas and has received multiple regulatory approvals. The company is expanding its pipeline with innovative ADCs for solid tumors and hematologic malignancies, leveraging strategic partnerships to enhance global access and address significant unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated about 1 year ago.